Aug 2026· Pharmaceutics· Vol 18· 0 citations· 145 references
Medicine
TL;DR
This review provides a concise framework for the rational design of programmable, multi-responsive polymeric nanomedicines for TNBC therapy and summarizes recent advances in pH-, redox-, ROS-, hypoxia-, photo- and temperature-responsive polymers.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype lacking effective targeted therapies. Its tumor microenvironment (TME) exhibits distinct features, including acidity, redox imbalance, elevated reactive oxygen species (ROS), and hypoxia, which provide exploitable triggers for targeted drug delivery. Stimuli-responsive polymeric nanocarriers have emerged as promising platforms that enable spatiotemporally controlled and site-specific therapeutic release in response to these endogenous cues, as well as exogenous stimuli such as temperature and light. These systems improve drug accumulation, penetration, and therapeutic efficacy while reducing systemic toxicity. Unlike previous reviews that broadly discuss nanocarriers in cancer therapy, this review focuses on the structure–function relationships of TME-responsive polymeric systems in TNBC and their translational limitations. We summarize recent advances in pH-, redox-, ROS-, hypoxia-, photo- and temperature-responsive polymers, highlighting their design strategies and therapeutic applications. Key challenges, including stimulus heterogeneity, limited in vivo validation, and clinical translation barriers, are also discussed. This review provides a concise framework for the rational design of programmable, multi-responsive polymeric nanomedicines for TNBC therapy.
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by high invasiveness, frequent recurrence, and metastasis, along with limited targeted therapeutic options. Despite clinical advances achieved with immune checkpoint inhibitors, poly(ADP-ribose) polymerase (PARP) inhibitors, and a...
Zhen-Xiao Wang, Mo Li, Zhen-Yu Wang et al.· Frontiers in Immunology· 0 citations
The evidence supports a conceptual transition from passive nanocarriers to programmable therapeutic systems capable of aligning therapeutic action with the spatial, temporal, and biological heterogeneity of tumors, but translation remains constrained by formulation complexity, incomplete standardization, limited long-t...
Hamid Omidian, Renae L. Wilson· Frontiers in Bioengineering...· 1 citation
Abstract Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and its poor prognosis, chemoresistance, and limited immunotherapy response are closely linked to pathological remodeling of the tumor microenvironment (TME). Targeting the TME has emerged as a promising strategy, but convention...
Yong-Xuan Long, Hong-Yu Yin, Jin-Bo Li et al.· International Journal of Nan...· 0 citations
This review systematically summarizes targeted nanomedicines constructed from mainstream carriers, including polymeric, metallic, and biomimetic nanoparticles, and discusses the future prospects of artificial intelligence-assisted optimization strategies for nanomedicine development.
Rui-Chao Li, Ze-Yuan Sun, Si-Nian Li et al.· International Journal of Pha...· 0 citations
The paper reviews current developments concerning stimulus-responsive nanoparticles; it also describes how these agents work as a means to treat cancers precisely.
C. J. Jiflin, Mohana Sundaram Somasundharam Pushpanathan, Jeevitha Dhayalan et al.· BOHR Journal of Pharmaceutic...· 0 citations
Acidity, hypoxia, redox imbalance, and altered enzyme activity in the tumor microenvironment (TME) can be used to regulate nanocarrier structure and drug release. However, these conditions vary among tumors and across regions within individual tumors and overlap with certain normal physiological and inflammatory proces...
Xiu-Lin Wen, Yong-Xin Jiang, Han-Jing Yang et al.· Journal of Nanotheranostics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.